去纤苷（defiteli）适应症

What are the indications for defiteli (defiteli, defibrinated sodium)? Hepatic veno-occlusive disease (HVOD) is one of the serious complications after hematopoietic stem cell transplantation (HSCT), and the mortality rate in patients with severe HVOD can be as high as 100%. Defibrotide (defiteli, defibrotide sodium) is an important drug suitable for the treatment of hepatic veno-occlusive disease.

Defibrotide (defiteli, defibrotide sodium) is a single-stranded oligonucleotide mixture that has anti-thrombotic and fibrinolytic effects. In recent years, multiple clinical research results have shown that defiteli (defiber sodium) is a safe and effective drug for preventing and treating HVOD after HSCT. Defiteli (defiber sodium) was first developed by Gentium Pharmaceuticals in Italy and was approved for marketing in the EU in October 2013. After Gentium Pharmaceuticals was acquired by American Jazz Pharmaceuticals, defiteli (defiteli sodium) was approved by the US Food and Drug Administration (FDA) to be launched in the United States on March 30, 2016, under the trade name Defitelio. 

Defibrotide (defiteli, defibrotide sodium) is a mixture of single-stranded oligonucleotides broken down from genomic DNA from calf lung or pig intestinal mucosa. The oligonucleotide chain length of DF varies, the relative molecular mass ranges from 15×10³-30×10³, and its purine to pyrimidine ratio is greater than 0.85. The mechanism of action of defiteli (defiber sodium) is relatively complex and is not yet fully understood. Preclinical trials have confirmed that defiteli has anti-thrombotic, fibrinolytic, anti-ischemic, and anti-infective effects in vivo and in vitro. The recommended dose of defiteli (defiteli sodium) for adult and pediatric patients is 6.25 mg/kg given every 6 hours as a 2-hour intravenous infusion. The dose should be based on the patient's baseline weight, which is defined as the patient's weight before the HSCT preparation protocol. Defibrotide was administered for a minimum of 21 days. If signs and symptoms of hepatic VOD have not resolved after 21 days, continue defibrotide until resolution of VOD or up to a maximum of 60 days. Do not coadminister defiteli (defiteli) with other intravenous drugs in the same intravenous line at the same time.

The above are the indications and functions of defiteli (defiber sodium) provided to you by our medical partner travel overseas medical consulting service company. From the above data, we can know that defiteli (defiber sodium) is an effective drug for the treatment of hepatic veno-occlusive disease.